Dr Metters has over 25 years of experience in the discovery and development of novel therapies for treatment of serious diseases. She is currently working as an independent biopharma consultant, and board member. From 2011-2014 Dr Metters was President and Chief Executive officer for Lycera Corp., a biopharmaceutical company initiating approaches to novel oral medicines for treatment of autoimmune diseases and cancer. From 1988 to 2011 Dr Metters was employed by Merck & Co in various roles. From 2002 to 2005 Dr Metters was head of research at Merck Frosst, Canada. During this time, she was the Basic Research Therapeutic Area Head for the Respiratory Franchise and from 2003-2005 was chair of the Respiratory Worldwide Business Strategy Team, reporting directing to the CEO, with responsibility for the discovery, development and commercialization strategy for respiratory products. Prior to that Dr Metters worked on research focused on the arachidonic acid cascade which resulted in the development of SINGULAIR, a once-daily oral therapy for asthma and allergic rhinitis.
